Journal article

Azithromycin-containing intermittent preventive treatment in pregnancy affects gestational weight gain, an important predictor of birthweight in Papua New Guinea - an exploratory analysis

Holger W Unger, Regina A Wangnapi, Maria Ome-Kaius, Philippe Boeuf, Stephan Karl, Ivo Mueller, Stephen J Rogerson

Maternal and Child Nutrition | WILEY | Published : 2016


In Papua New Guinea, intermittent preventive treatment with sulphadoxine-pyrimethamine and azithromycin (SPAZ-IPTp) increased birthweight despite limited impact on malaria and sexually transmitted infections. To explore possible nutrition-related mechanisms, we evaluated associations between gestational weight gain (GWG), enrolment body mass index (BMI) and mid-upper arm circumference (MUAC), and birthweight. We investigated whether the increase in birthweight associated with SPAZ-IPTp may partly be driven by a treatment effect on GWG. The mean GWG rate was 393 g/week (SD 250; n = 948). A 100 g/week increase in GWG was associated with a 14 g (95% CI 2.6, 25.4) increase in birthweight (P = 0...

View full abstract


Awarded by Malaria in Pregnancy Consortium from the Bill & Melinda Gates Foundation

Awarded by Pregvax Consortium from the European Union

Awarded by Pfizer Inc

Awarded by NHMRC

Funding Acknowledgements

This research was supported by the Malaria in Pregnancy Consortium, through a grant from the Bill & Melinda Gates Foundation (46099); the Pregvax Consortium, through a grant from the European Union's Seventh Framework Programme FP7-2007-HEALTH (PREGVAX 201588); and Pfizer Inc (investigator-initiated research grant WS394663). SK is supported through an NHMRC Early Career Fellowship (GNT1052960), and IM received an NHMRC Senior Research Fellowship (#1043345). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.